Mindfulness program to improve quality of life in patients with drug-resistant epilepsy
Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.
This study is testing whether a mindfulness program can help improve the quality of life for people with drug-resistant epilepsy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 3 sites (Grenoble and 2 other locations) |
| Trial ID | NCT04126369 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a mindfulness intervention in improving the quality of life for patients suffering from drug-resistant epilepsy. Participants will be randomly assigned to either a mindfulness program or a psychoeducative self-management program, with both interventions lasting three months. The study includes a two-month baseline assessment followed by a six-month post-intervention follow-up to evaluate changes in emotional management and quality of life. Participants will also maintain a daily log of their seizures and emotional state throughout the study.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with drug-resistant epilepsy who have stable therapy and are not currently practicing mindfulness.
Not a fit: Patients with psychogenic non-epileptic seizures or those who have previously practiced mindfulness may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life for patients with drug-resistant epilepsy by improving their emotional well-being.
How similar studies have performed: Other studies have shown promising results using mindfulness interventions for chronic conditions, suggesting potential success for this approach in epilepsy management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Drug resistant epilepsy according to the criteria of the International League Against Epilepsy (ILAE) * Stable therapy for at least 3 months * No planned surgery * Patient affiliated to social security insurance or beneficiary of social security insurance. * Signed consent Exclusion Criteria: * Patient who has previously had or regularly practicing mindfulness * Patient with psychogenic non-epileptic seizures * Pregnant woman, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to legal protection * Patient with relationship disorders related to psychosis * Patients who are unable or unwilling to work as a group or person unable to understand the topics discussed during session.
Where this trial is running
Grenoble and 2 other locations
- Epileptology Department of The Grenoble University Hospital — Grenoble, France (Recruiting)
- Epileptology Department of the Lyon University Hospital — Lyon, France (Not_yet_recruiting)
- La Teppe medical centre — Tain-l'Hermitage, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Cécile SABOURDY, MD
- Email: CSabourdy@chu-grenoble.fr
- Phone: 04767656.9
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.